ESMO 2024: Focus on GI Oncology
Advertisement
Dr. Weinberg provides a recap of all of the GI oncology data of practice-changing potential presented at ESMO 2024.
HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.
Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.
Retifanlimab plus chemotherapy showed improved PFS and response rates in locally recurrent or metastatic SCAC.
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
mFOLFIRINOX plus CRT did not improve R0 resection nor OS compared with nFOLFIRINOX without CRT.
Dr. Leong showcases the highly anticipated results of the TOPGEAR study in patients with resectable G/GEJ adenocarcinoma.
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.
FLOT and nivo seems to be associated with improved efficacy, whereas chemo followed by IO therapy is insufficient.
The LEAP-012 study showed improved progression-free survival with lenvatinib, pembrolizumab, and TACE in HCC.
The addition of preop CRT to periop chemo may not have added OS benefit for patients with resectable G/GEJ adenocarcinoma.
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Dr. Josep Llovet discusses promising data, including higher PFS and OS, in metastatic liver cancer from the LEAP-012 trial.
Dr. Janjigian shares an overview of the DESTINY-Gastric03 study and the history of T-Dxd for gastric and GEJ cancers.
Combining encorafenib and cetuximab with FOLFIRI chemotherapy showed strong antitumor activity in BRAF V600E-mutant mCRC.
Trastuzumab deruxtecan, pembrolizumab, and chemotherapy shows benefits in advanced or metastatic esophageal, gastric, or GEJA
Cabozantinib continues to demonstrate significant improvement in PFS in extra-pancreatic or pancreatic neuroendocrine tumors.
Amivantamab plus chemo shows encouraging and durable antitumor activity for anti-EGFR-naïve RAS/RAF wild-type mCRC.
Neoadjuvant nivolumab plus relatlimab led to a pathologic response rate of 96%.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.